US FDA declines to approve Outlook Therapeutics' drug for eye condition – Reuters

1. US FDA declines to approve Outlook Therapeutics’ drug for eye condition  Reuters
2. FDA again rejects Outlook Therapeutics’ version of Avastin for wet AMD  Endpoints News
3. Outlook Therapeutics Stock Nose-Dives 66% In Pre-Market – Here’s Why  MSN
4. FDA Issues CRL to Outlook Therapeutics’ ONS-5010 for the Treatment of Wet AMD  HCPLive
5. Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD  Yahoo Finance

Continue Reading